Yu Qin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yu Qin has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
Chenlu Huang
5 shared publicationsChun Wang
Department of Biomedical Engineering, University of Minnesota, 7-116 Hasselmo Hall, 312 Church Street S.E., Minneapolis, MN 55455, USA
4 shared publications- Dunwan Zhu
State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Engineering, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300192, China
4 shared publications Fan Fan
Institute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin Key Laboratory of Biomedical Materials, Tianjin 300192, China
4 shared publicationsHongfan Sun
Institute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin Key Laboratory of Biomedical Materials, Tianjin 300192, China
4 shared publicationsXigang Leng
Institute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin Key Laboratory of Biomedical Materials, Tianjin 300192, China
4 shared publications
Latest Publications
- 20 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (47)
Nanoparticle-enabled gene delivery for pediatric brain tumors
Pediatric brain tumors are the leading cause of disease-related death in children, yet effective treatment remains a major clinical challenge. These aggressive tumors have limited therapeutic options capable of crossing the blood-brain barrier (BBB) and frequently recur due to genetic or epigenetic alterations and treatment resistance. Gene therapy offers a promising strategy to address these limitations by modifying gene expression, correcting mutations, or introducing functional genes. Nanoparticle (NP) delivery systems facilitate this approach by protecting genetic cargo and enabling BBB penetration and tumor-specific uptake. This review summarizes current genetic engineering strategies and NP-based delivery systems for pediatric brain tumors, including their design principles and delivery mechanisms, highlights key therapeutic approaches under preclinical and clinical investigations, and discusses the major challenges and future directions in NP-mediated gene therapy for pediatric neuro-oncology. By critically evaluating these developments, we aim to underscore the transformative potential of NP-mediated gene therapies in reshaping treatment paradigms and improving outcomes and quality of life for children.
- 20 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (47)
Nanoparticle-enabled gene delivery for pediatric brain tumors
Pediatric brain tumors are the leading cause of disease-related death in children, yet effective treatment remains a major clinical challenge. These aggressive tumors have limited therapeutic options capable of crossing the blood-brain barrier (BBB) and frequently recur due to genetic or epigenetic alterations and treatment resistance. Gene therapy offers a promising strategy to address these limitations by modifying gene expression, correcting mutations, or introducing functional genes. Nanoparticle (NP) delivery systems facilitate this approach by protecting genetic cargo and enabling BBB penetration and tumor-specific uptake. This review summarizes current genetic engineering strategies and NP-based delivery systems for pediatric brain tumors, including their design principles and delivery mechanisms, highlights key therapeutic approaches under preclinical and clinical investigations, and discusses the major challenges and future directions in NP-mediated gene therapy for pediatric neuro-oncology. By critically evaluating these developments, we aim to underscore the transformative potential of NP-mediated gene therapies in reshaping treatment paradigms and improving outcomes and quality of life for children.
- Open Access
- 26 June 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (24) , e2500195
Semiconducting Polymer Nanoparticles as Multimodal Agents for Optical and Magnetic Resonance Imaging
Semiconducting polymer nanoparticles (SPNs) are a very promising class of fluorescent nanoparticles that exhibit many advantageous optical and biological properties. However, their potential for optical imaging in clinical applications is currently restricted by limited tissue penetration. Multimodal SPN‐based contrast agents that integrate several imaging modalities into one platform are able to yield a wealth of information through the use of different imaging mechanisms. The inclusion of magnetic resonance imaging (MRI), with its good spatial resolution and deep tissue penetration, enables SPNs to combine the complementary advantages of MRI and optical imaging. This short review explores the approaches adopted in the literature in the nascent field of multimodal optical‐MRI SPN‐based probes.
- 26 June 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (24) , e2500195
Open AccessSemiconducting Polymer Nanoparticles as Multimodal Agents for Optical and Magnetic Resonance Imaging
Semiconducting polymer nanoparticles (SPNs) are a very promising class of fluorescent nanoparticles that exhibit many advantageous optical and biological properties. However, their potential for optical imaging in clinical applications is currently restricted by limited tissue penetration. Multimodal SPN‐based contrast agents that integrate several imaging modalities into one platform are able to yield a wealth of information through the use of different imaging mechanisms. The inclusion of magnetic resonance imaging (MRI), with its good spatial resolution and deep tissue penetration, enables SPNs to combine the complementary advantages of MRI and optical imaging. This short review explores the approaches adopted in the literature in the nascent field of multimodal optical‐MRI SPN‐based probes.
- 7 October 2023
- Published by Elsevier in Chinese Chemical Letters
- Vol. 35 (7)
O2-generating multifunctional polymeric micelles for highly efficient and selective photodynamic-photothermal therapy in melanoma
- 7 October 2023
- Published by Elsevier in Chinese Chemical Letters
- Vol. 35 (7)
O2-generating multifunctional polymeric micelles for highly efficient and selective photodynamic-photothermal therapy in melanoma
- Open Access
- 12 September 2023
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 102 (6) , 1553-1567
Design, synthesis, and evaluation of the in vitro activity of novel dual inhibitors of XOR and URAT1 containing a benzoic acid group
Xanthine oxidoreductase (XOR) and uric acid transporter 1 (URAT1) are involved in the production and reabsorption of uric acid, respectively. However, the currently available individual XOR‐ or URAT1‐targeted drugs have limited efficacy. Thus, strategies for combining XOR inhibitors with uricosuric drugs have been developed. Previous virtual screening identified Compounds 1–5 as hits for the potential dual inhibition of XOR/URAT1. Nevertheless, in vitro experiments yielded unsatisfactory results. The first round of optimization work on those hits was performed, and two series of compounds were designed and synthesized. Compounds of the A series exerted moderate inhibitory effects on URAT1, but extremely weak inhibitory effects on XOR. Compounds of the B series exerted strong inhibitory effects on both XOR and URAT1. B5 exhibited the greatest inhibitory activity, with similar inhibitory effects on XOR and URAT1. The half maximal inhibitory concentration (IC50) of XOR was 0.012 ± 0.001 μM, equivalent to that of febuxostat (IC50 = 0.010 ± 0.001 μM). The IC50 of URAT1 was 30.24 ± 3.46 μM, equivalent to that of benzbromarone (IC50 = 24.89 ± 7.53 μM). Through this optimization, the in vitro activity of most compounds of the A and B series against XOR and URAT1 was significantly improved versus that of the hits. Compound B5 should be further investigated.
- 12 September 2023
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 102 (6) , 1553-1567
Open AccessDesign, synthesis, and evaluation of the in vitro activity of novel dual inhibitors of XOR and URAT1 containing a benzoic acid group
Xanthine oxidoreductase (XOR) and uric acid transporter 1 (URAT1) are involved in the production and reabsorption of uric acid, respectively. However, the currently available individual XOR‐ or URAT1‐targeted drugs have limited efficacy. Thus, strategies for combining XOR inhibitors with uricosuric drugs have been developed. Previous virtual screening identified Compounds 1–5 as hits for the potential dual inhibition of XOR/URAT1. Nevertheless, in vitro experiments yielded unsatisfactory results. The first round of optimization work on those hits was performed, and two series of compounds were designed and synthesized. Compounds of the A series exerted moderate inhibitory effects on URAT1, but extremely weak inhibitory effects on XOR. Compounds of the B series exerted strong inhibitory effects on both XOR and URAT1. B5 exhibited the greatest inhibitory activity, with similar inhibitory effects on XOR and URAT1. The half maximal inhibitory concentration (IC50) of XOR was 0.012 ± 0.001 μM, equivalent to that of febuxostat (IC50 = 0.010 ± 0.001 μM). The IC50 of URAT1 was 30.24 ± 3.46 μM, equivalent to that of benzbromarone (IC50 = 24.89 ± 7.53 μM). Through this optimization, the in vitro activity of most compounds of the A and B series against XOR and URAT1 was significantly improved versus that of the hits. Compound B5 should be further investigated.
- Open Access
- 13 November 2020
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 10 (68) , 41471-41481
A brain glioma gene delivery strategy by angiopep-2 and TAT-modified magnetic lipid-polymer hybrid nanoparticles
Owing to the existence of the blood–brain barrier (BBB), most treatments cannot achieve significant effects on gliomas. In this study, synergistic multitarget Ang-TAT-Fe3O4-pDNA-(ss)373 lipid-polymer hybrid nanoparticles (LPNPs) were designed to penetrate the BBB and deliver therapeutic genes to glioma cells. The basic material of the nanoparticles was PCL3750-ss-PEG7500-ss-PCL3750, and is called (ss)373 herein. (ss)373 NPs, Fe3O4 magnetic nanoparticles (MNPs), DOTAP, and DSPE-PEG-MAL formed the basic structure of LPNPs by self-assembly. The Fe3O4 MNPs were wrapped in (ss)373 NPs to implement magnetic targeting. Then, the Angiopep-2 peptide (Ang) and transactivator of transcription (TAT) were coupled with DSPE-PEG-MAL. Both can enhance BBB penetration and tumor targeting. Finally, the pDNA was compressed on DOTAP to form the complete gene delivery system. The results indicated that the Ang-TAT-Fe3O4-pDNA-(ss)373 LPNPs were 302.33 nm in size. In addition, their zeta potential was 4.66 mV, and they had good biocompatibility. The optimal nanoparticles/pDNA ratio was 5 : 1, as shown by gel retardation assay. In this characterization, compared with other LPNPs, the modified single Ang or without the addition of the Fe3O4 MNPs, the penetration efficiency of the BBB model formed by hCMEC/D3 cells, and the transfection efficiency of C6 cells using pEGFP-C1 as the reporter gene were significantly improved with Ang-TAT-Fe3O4-pDNA-(ss)373 LPNPs in the magnetic field.
- 13 November 2020
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 10 (68) , 41471-41481
Open AccessA brain glioma gene delivery strategy by angiopep-2 and TAT-modified magnetic lipid-polymer hybrid nanoparticles
Owing to the existence of the blood–brain barrier (BBB), most treatments cannot achieve significant effects on gliomas. In this study, synergistic multitarget Ang-TAT-Fe3O4-pDNA-(ss)373 lipid-polymer hybrid nanoparticles (LPNPs) were designed to penetrate the BBB and deliver therapeutic genes to glioma cells. The basic material of the nanoparticles was PCL3750-ss-PEG7500-ss-PCL3750, and is called (ss)373 herein. (ss)373 NPs, Fe3O4 magnetic nanoparticles (MNPs), DOTAP, and DSPE-PEG-MAL formed the basic structure of LPNPs by self-assembly. The Fe3O4 MNPs were wrapped in (ss)373 NPs to implement magnetic targeting. Then, the Angiopep-2 peptide (Ang) and transactivator of transcription (TAT) were coupled with DSPE-PEG-MAL. Both can enhance BBB penetration and tumor targeting. Finally, the pDNA was compressed on DOTAP to form the complete gene delivery system. The results indicated that the Ang-TAT-Fe3O4-pDNA-(ss)373 LPNPs were 302.33 nm in size. In addition, their zeta potential was 4.66 mV, and they had good biocompatibility. The optimal nanoparticles/pDNA ratio was 5 : 1, as shown by gel retardation assay. In this characterization, compared with other LPNPs, the modified single Ang or without the addition of the Fe3O4 MNPs, the penetration efficiency of the BBB model formed by hCMEC/D3 cells, and the transfection efficiency of C6 cells using pEGFP-C1 as the reporter gene were significantly improved with Ang-TAT-Fe3O4-pDNA-(ss)373 LPNPs in the magnetic field.
- 1 June 2020
- Published by Elsevier in Journal of Controlled Release
- Vol. 322, 566-592
Stimuli-responsive nano-assemblies for remotely controlled drug delivery
- 1 June 2020
- Published by Elsevier in Journal of Controlled Release
- Vol. 322, 566-592
Stimuli-responsive nano-assemblies for remotely controlled drug delivery
- 23 March 2020
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 12 (15) , 8040-8064
Recent advances in molecular imaging of atherosclerotic plaques and thrombosis
Recent advances in emerging molecular imaging techniques bring new opportunities in the diagnosis of atherosclerosis plaques and thrombosis.
- 23 March 2020
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 12 (15) , 8040-8064
Recent advances in molecular imaging of atherosclerotic plaques and thrombosis
Recent advances in emerging molecular imaging techniques bring new opportunities in the diagnosis of atherosclerosis plaques and thrombosis.
- 1 June 2019
- Published by Elsevier in Biomaterials
- Vol. 206, 25-40
Co-delivery of antigen and dual agonists by programmed mannose-targeted cationic lipid-hybrid polymersomes for enhanced vaccination
- 1 June 2019
- Published by Elsevier in Biomaterials
- Vol. 206, 25-40
Co-delivery of antigen and dual agonists by programmed mannose-targeted cationic lipid-hybrid polymersomes for enhanced vaccination
- 14 March 2019
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 19 (7) , 4237-4249
Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy
Among approaches of current cancer immunotherapy, dendritic cells (DCs)-targeted vaccine based on nanotechnology could be a promising way to efficiently induce potent immune responses. To enhance DCs targeting and vaccine efficiency, we included Imiquimod (IMQ), a toll-like receptor 7/8 (TLR 7/8) agonist and Monophosphoryl Lipid A (MPLA), a TLR4 agonist to synthesize lipid-polymer hybrid nanoparticles using PCL-PEG-PCL and DOTAP (IMNPs) as well as DSPE-PEG-mannose (MAN-IMNPS). The spatio-temporal delivery of MPLA (within outer lipid layer) to extracellular TLR4 and IMQ (in the hydrophobic core of NPs) to intracellular TLR7/8 can activate DCs synergistically to improve vaccine efficacy. Ovalbumin (OVA) as a model antigen was readily absorbed by positively charged DOTAP and showed a quick release in vitro. Our results demonstrated that this novel nanovaccine enhanced cellular uptake, cytokines production and maturation of DCs. Compared with quick metabolism of free OVA-agonists, depot effect of OVA-IMNPs was observed whereas MAN-OVA-IMNPs promoted trafficking to secondary lymphoid organs. After immunization with subcutaneous injection, nanovaccine, especially MAN-OVA-IMNPs induced more antigen-specific CD8+ T cells, greater lymphocyte activation, stronger cross-presentation, and more generation of memory T cells, antibody, IFN-γ, and Granzyme B. Prophylactic vaccination of MAN-OVA-IMNPs significantly delayed tumor development and prolonged survival in mice. Therapeutic tumor challenge indicated that MAN-OVA-IMNPs prohibited tumor progression more efficiently than other formulations and the combination with immune checkpoint blockade further enhanced antitumor effects. Hence, DCs-targeted vaccine co-delivery with IMQ and MPLA adjuvants by hybrid cationic nanoparticles in a spatio-temporal manner is a promising multifunctional antigen delivery system in cancer immunotherapy.
- 14 March 2019
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 19 (7) , 4237-4249
Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy
Among approaches of current cancer immunotherapy, dendritic cells (DCs)-targeted vaccine based on nanotechnology could be a promising way to efficiently induce potent immune responses. To enhance DCs targeting and vaccine efficiency, we included Imiquimod (IMQ), a toll-like receptor 7/8 (TLR 7/8) agonist and Monophosphoryl Lipid A (MPLA), a TLR4 agonist to synthesize lipid-polymer hybrid nanoparticles using PCL-PEG-PCL and DOTAP (IMNPs) as well as DSPE-PEG-mannose (MAN-IMNPS). The spatio-temporal delivery of MPLA (within outer lipid layer) to extracellular TLR4 and IMQ (in the hydrophobic core of NPs) to intracellular TLR7/8 can activate DCs synergistically to improve vaccine efficacy. Ovalbumin (OVA) as a model antigen was readily absorbed by positively charged DOTAP and showed a quick release in vitro. Our results demonstrated that this novel nanovaccine enhanced cellular uptake, cytokines production and maturation of DCs. Compared with quick metabolism of free OVA-agonists, depot effect of OVA-IMNPs was observed whereas MAN-OVA-IMNPs promoted trafficking to secondary lymphoid organs. After immunization with subcutaneous injection, nanovaccine, especially MAN-OVA-IMNPs induced more antigen-specific CD8+ T cells, greater lymphocyte activation, stronger cross-presentation, and more generation of memory T cells, antibody, IFN-γ, and Granzyme B. Prophylactic vaccination of MAN-OVA-IMNPs significantly delayed tumor development and prolonged survival in mice. Therapeutic tumor challenge indicated that MAN-OVA-IMNPs prohibited tumor progression more efficiently than other formulations and the combination with immune checkpoint blockade further enhanced antitumor effects. Hence, DCs-targeted vaccine co-delivery with IMQ and MPLA adjuvants by hybrid cationic nanoparticles in a spatio-temporal manner is a promising multifunctional antigen delivery system in cancer immunotherapy.
- 1 October 2018
- Published by American Scientific Publishers in Journal of Biomedical Nanotechnology
- Vol. 14 (10) , 1705-1718
Folate-Targeted Redox-Responsive Polymersomes Loaded with Chemotherapeutic Drugs and Tariquidar to Overcome Drug Resistance
Tumor multidrug resistance (MDR) is a fatal obstacle to cancer chemotherapy. The combination of P-glycoprotein (P-gp) inhibitor and chemotherapeutic drugs is one of the effective strategies to reverse tumor MDR. Herein, a folate-decorated PCL-ss-PEG-ss-PCL based redox-responsive polymersome (FA-TQR-Co-PS) was constructed, which was loaded with P-gp inhibitor tariquidar (TQR), anticancer drugs doxorubicin (DOX) and paclitaxel (PTX). The results suggested that the FA-TQR-Co-PS with an apparent bilayered lamellar structure displayed good monodispersity, high drug loading capacity, superior stability and redox-stimulated drug release peculiarity. In vitro cellular uptake study demonstrated that FA-TQR-Co-PS increased drug accumulation into MCF-7/ADR cells via the TQR-induced P-gp efflux inhibition, and further improved targeting to tumor cells due to folate receptor-mediated endocytosis. Furthermore, the DOX and PTX cytotoxicity and proapoptotic activity against MCF-7/ADR was enhanced dramatically along with the administration of TQR, and the cell cycle was profoundly blocked in G2/M phase. The folate-targeted redox-responsive polymersomes loaded with chemotherapeutic drugs and P-gp inhibitor demonstrated noticeable synergistic effect against human MDR MCF-7 cells and successfully reversed drug resistance, which displayed high potential in overcoming tumor MDR as a novel drug delivery system.
- 1 October 2018
- Published by American Scientific Publishers in Journal of Biomedical Nanotechnology
- Vol. 14 (10) , 1705-1718
Folate-Targeted Redox-Responsive Polymersomes Loaded with Chemotherapeutic Drugs and Tariquidar to Overcome Drug Resistance
Tumor multidrug resistance (MDR) is a fatal obstacle to cancer chemotherapy. The combination of P-glycoprotein (P-gp) inhibitor and chemotherapeutic drugs is one of the effective strategies to reverse tumor MDR. Herein, a folate-decorated PCL-ss-PEG-ss-PCL based redox-responsive polymersome (FA-TQR-Co-PS) was constructed, which was loaded with P-gp inhibitor tariquidar (TQR), anticancer drugs doxorubicin (DOX) and paclitaxel (PTX). The results suggested that the FA-TQR-Co-PS with an apparent bilayered lamellar structure displayed good monodispersity, high drug loading capacity, superior stability and redox-stimulated drug release peculiarity. In vitro cellular uptake study demonstrated that FA-TQR-Co-PS increased drug accumulation into MCF-7/ADR cells via the TQR-induced P-gp efflux inhibition, and further improved targeting to tumor cells due to folate receptor-mediated endocytosis. Furthermore, the DOX and PTX cytotoxicity and proapoptotic activity against MCF-7/ADR was enhanced dramatically along with the administration of TQR, and the cell cycle was profoundly blocked in G2/M phase. The folate-targeted redox-responsive polymersomes loaded with chemotherapeutic drugs and P-gp inhibitor demonstrated noticeable synergistic effect against human MDR MCF-7 cells and successfully reversed drug resistance, which displayed high potential in overcoming tumor MDR as a novel drug delivery system.